Richard Y. Lam

778 total citations
26 papers, 518 citations indexed

About

Richard Y. Lam is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Richard Y. Lam has authored 26 papers receiving a total of 518 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 5 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Richard Y. Lam's work include Prostate Cancer Treatment and Research (13 papers), Prostate Cancer Diagnosis and Treatment (6 papers) and Hormonal and reproductive studies (5 papers). Richard Y. Lam is often cited by papers focused on Prostate Cancer Treatment and Research (13 papers), Prostate Cancer Diagnosis and Treatment (6 papers) and Hormonal and reproductive studies (5 papers). Richard Y. Lam collaborates with scholars based in United States, United Kingdom and Italy. Richard Y. Lam's co-authors include Mark C. Scholz, Robert I. Jennrich, Stephen B. Strum, Henry J. Johnson, Lawrence A. Cone, Jeffrey S. Turner, Milton T. M. Little, John Garlich, Michael Albert and Benjamin Noah and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Richard Y. Lam

25 papers receiving 502 citations

Peers

Countries citing papers authored by Richard Y. Lam

Since Specialization

Citations

This map shows the geographic impact of Richard Y. Lam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Y. Lam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Y. Lam more than expected).

Fields of papers citing papers by Richard Y. Lam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Y. Lam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Y. Lam. The network helps show where Richard Y. Lam may publish in the future.

Co-authorship network of co-authors of Richard Y. Lam

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Y. Lam. A scholar is included among the top collaborators of Richard Y. Lam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Y. Lam. Richard Y. Lam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting C1q signaling in fibro-adipogenic progenitors prevents regenerative fibrosis of aged muscle 2026 ·Proceedings of the National Academy of Sciences ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Richard Y. Lam, Stefano Biressi, (unknown), (unknown)	0
2	Cellular survivorship bias as a mechanistic driver of muscle stem cell aging 2026 ·Science ·(unknown), Daniel I. Benjamin, Qiqi Guo, (unknown), (unknown), (unknown), (unknown), Mingyu Chung, (unknown), (unknown), Richard Y. Lam, (unknown)	1
3	Depletion of SAM leading to loss of heterochromatin drives muscle stem cell ageing 2024 ·Nature Metabolism ·Jengmin Kang, Daniel I. Benjamin, Soochi Kim, Jayesh S. Salvi, G. K. Dhaliwal, Richard Y. Lam, (unknown), Jamie O. Brett, Ling Liu, Thomas A. Rando	31
4	The pharmacologic and toxicologic characterization of the potent and selective KRAS G12D inhibitors ERAS-4693 and ERAS-5024 2023 ·Toxicology and Applied Pharmacology ·Alexei Brooun, Jingchuan Zhang, (unknown), Richard Y. Lam, Hengmiao Cheng, (unknown), Jennifer S. Daly, Andrew Olaharski	2
5	PSMA-Negative Lesion Progression Under¹⁷⁷Lu-PSMA Radioligand Therapy 2023 ·Journal of Nuclear Medicine ·Vishnu Murthy, Martin Allen-Auerbach, Richard Y. Lam, Dawn Owen, Johannes Czernin, Jérémie Calais	4
6	Virtual reality for management of pain in hospitalized patients: A randomized comparative effectiveness trial 2019 ·PLoS ONE ·Brennan Spiegel, Garth Fuller, Mayra Lopez, Taylor Dupuy, Benjamin Noah, (unknown), Michael Albert, Vartan C. Tashjian, Richard Y. Lam, (unknown), Francis Dailey, Bradley T. Rosen, Mark S. Vrahas, Milton T. M. Little, John Garlich, Eldin Dzubur, Waguih William IsHak, Itai Danovitch	144
7	Pembrolizumab for recurrent or advanced prostate cancer. 2018 ·Journal of Clinical Oncology ·(unknown), (unknown), Joanne B. Weidhaas, (unknown), Richard Y. Lam, Jeffrey S. Turner, Mark C. Scholz	5
8	Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer 2017 ·ImmunoTargets and Therapy ·Mark C. Scholz, (unknown), (unknown), Colleen Kelly, (unknown), Jeffrey S. Turner, Richard Y. Lam, Charles G. Drake	49
9	Performance characteristics and relationship of PSA value/kinetics on carbon-11 acetate PET/CT imaging in biochemical relapse of prostate cancer. 2017 ·PubMed ·Fábio Almeida, (unknown), Mark C. Scholz, Richard Y. Lam, Jeffrey S. Turner, (unknown), (unknown)	9
10	Anesthesia Case of the Month 2016 ·Journal of the American Veterinary Medical Association ·(unknown), Richard Y. Lam, Jaime Viscasillas	1
11	Primary androgen deprivation (AD) followed by active surveillance (AS) for newly diagnosed prostate cancer (PC): A retrospective study 2012 ·The Prostate ·Mark C. Scholz, (unknown), (unknown), Stephen B. Strum, Robert I. Jennrich, Duke Bahn, (unknown), (unknown), Richard Y. Lam	2
12	Primary Intermittent Androgen Deprivation As Initial Therapy for Men with Newly Diagnosed Prostate Cancer 2011 ·Clinical Genitourinary Cancer ·Mark C. Scholz, Richard Y. Lam, Stephen B. Strum, (unknown), (unknown), (unknown), (unknown), Robert I. Jennrich	8
13	Prostate Cancer-Specific Survival and Clinical Progression-Free Survival in Men with Prostate Cancer Treated Intermittently with Testosterone Inactivating Pharmaceuticals 2007 ·Urology ·Mark C. Scholz, Richard Y. Lam, Stephen B. Strum, Robert I. Jennrich, Henry J. Johnson, (unknown)	10
14	Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time Off Period 2006 ·The Journal of Urology ·Mark C. Scholz, Robert I. Jennrich, Stephen B. Strum, Henry J. Johnson, (unknown), Richard Y. Lam	24
15	Ultrasensitive PSA nadir on testosterone inactivating pharmaceuticals accurately predicts early prostate cancer progression 2006 ·Journal of Clinical Oncology ·Mark C. Scholz, Richard Y. Lam, (unknown), Stephen B. Strum, Henry J. Johnson, (unknown)	1
16	Preventing and Treating the Side Effects of Testosterone Inactivating Pharmaceuticals in Men with Prostate Cancer 2006 ·(unknown), Mark C. Scholz, Richard Y. Lam	3
17	Oral bisphosphonates fail to prevent bone loss from androgen deprivation therapy in men with prostate cancer 2006 ·Journal of Clinical Oncology ·Richard Y. Lam, M. Scholz, (unknown), (unknown)	1
18	High Dose Ketoconazole Plus Hydrocortisone (HDK+ HC) 2004 ·Richard Y. Lam	1
19	Multiple cerebral abscesses because of listeria monocytogenes: three case reports and a literature review of supratentorial listerial brain abscess(es) 2003 ·Surgical Neurology ·Lawrence A. Cone, (unknown), (unknown), (unknown), Richard Y. Lam, (unknown)	65
20	Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study 2003 ·Prostate Cancer and Prostatic Diseases ·(unknown), Mark C. Scholz, Stephen B. Strum, Richard Y. Lam, Henry J. Johnson, Robert I. Jennrich	72

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact